Nkarta Inc
NKTX1.815USD
+0.025+1.40%
Market hours （ET）Quotes delayed by 15 min
128.91MMarket Cap
LossP/E TTM
More Details of Nkarta Inc Company
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Nkarta Inc Info
Ticker SymbolNKTX
Company nameNkarta Inc
IPO dateJul 10, 2020
CEOHastings (Paul J)
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 10
Address1150 Veterans Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone19254071049
Websitehttps://www.nkartatx.com/
Ticker SymbolNKTX
IPO dateJul 10, 2020
CEOHastings (Paul J)
Company Executives of Nkarta Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
New Enterprise Associates (NEA)
5.02%
Samsara BioCapital, LLC
4.94%
SR One Capital Management, LP
4.69%
Other
60.20%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
New Enterprise Associates (NEA)
5.02%
Samsara BioCapital, LLC
4.94%
SR One Capital Management, LP
4.69%
Other
60.20%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.89%
Hedge Fund
21.37%
Investment Advisor
15.34%
Investment Advisor/Hedge Fund
12.87%
Corporation
4.45%
Research Firm
2.00%
Individual Investor
0.82%
Family Office
0.09%
Bank and Trust
0.07%
Other
9.09%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
267
61.18M
86.14%
-27.32M
2025Q2
285
69.55M
98.01%
-21.71M
2025Q1
300
69.02M
97.27%
-22.80M
2024Q4
316
69.51M
100.26%
-10.53M
2024Q3
335
73.98M
106.61%
-9.96M
2024Q2
333
73.31M
105.81%
-2.74M
2024Q1
329
70.79M
102.89%
+13.14M
2023Q4
312
47.25M
96.07%
-11.76M
2023Q3
310
42.86M
87.43%
-15.68M
2023Q2
313
46.09M
94.31%
-14.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.81M
15.21%
--
--
Jun 30, 2025
Tang Capital Management, LLC
7.06M
9.93%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
3.57M
5.02%
--
--
Jun 30, 2025
Samsara BioCapital, LLC
3.77M
5.31%
--
--
Jun 30, 2025
SR One Capital Management, LP
3.33M
4.69%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.66M
5.15%
-352.29K
-8.79%
Jun 30, 2025
GSK plc
3.16M
4.45%
+3.16M
--
Mar 27, 2024
Citadel Advisors LLC
3.30M
4.64%
-210.67K
-6.00%
Jun 30, 2025
EQT Life Sciences
2.84M
3.99%
--
--
Feb 12, 2025
The Vanguard Group, Inc.
2.55M
3.6%
+29.18K
+1.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Nkarta Inc?
The top five shareholders of Nkarta Inc are:
RA Capital Management, LP holds 10.81M shares, accounting for 15.21% of the total shares.
Tang Capital Management, LLC holds 7.06M shares, accounting for 9.93% of the total shares.
New Enterprise Associates (NEA) holds 3.57M shares, accounting for 5.02% of the total shares.
Samsara BioCapital, LLC holds 3.77M shares, accounting for 5.31% of the total shares.
SR One Capital Management, LP holds 3.33M shares, accounting for 4.69% of the total shares.
RA Capital Management, LP holds 10.81M shares, accounting for 15.21% of the total shares.
Tang Capital Management, LLC holds 7.06M shares, accounting for 9.93% of the total shares.
New Enterprise Associates (NEA) holds 3.57M shares, accounting for 5.02% of the total shares.
Samsara BioCapital, LLC holds 3.77M shares, accounting for 5.31% of the total shares.
SR One Capital Management, LP holds 3.33M shares, accounting for 4.69% of the total shares.
What are the top three shareholder types of Nkarta Inc?
The top three shareholder types of Nkarta Inc are:
RA Capital Management, LP
Tang Capital Management, LLC
New Enterprise Associates (NEA)
RA Capital Management, LP
Tang Capital Management, LLC
New Enterprise Associates (NEA)
How many institutions hold shares of Nkarta Inc (NKTX)?
As of 2025Q3, 267 institutions hold shares of Nkarta Inc, with a combined market value of approximately 61.18M, accounting for 86.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.87%.
What is the biggest source of revenue for Nkarta Inc?
In FY2020, the -- business generated the highest revenue for Nkarta Inc, amounting to -- and accounting for --% of total revenue.
